Figure 1

Saracatinib combined with lapatinib synergistically inhibits survival of human breast cancer cell lines. (A) Percentage of survival of MDA-MB-361, SKBR-3, BT474, KPL-4, MDA-MB-361-LR, and JIMT-1 breast cancer cell lines grown in complete medium and treated with saracatinib, lapatinib, or both, measured by MTT assay. Data represent the mean (±standard deviation, SD) of three independent experiments, each performed in triplicate, and are presented relative to control (cells treated with DMSO). Error bars indicate SDs. Asterisks indicate statistical significance of combined treatment versus lapatinib alone determined with Student t test (*two-sided P < 0.5 × 10^-1; **two-sided P < 0.5 × 10^-2). (B) Western blot analysis of total cell lysates from MDA-MB-361, SKBR-3, BT474, KPL-4, MDA-MB-361-LR, and JIMT-1 breast cancer cell lines grown in complete medium. (C) Western blot analysis of total cell lysates from breast cancer cell lines grown in complete medium and treated with saracatinib (1 μM), lapatinib (1 μM), or both. The relative optical density of phospho-protein levels normalized to actin level is shown.